The Genomic Landscape of TP53 and p53 Annotated High Grade Ovarian Serous Carcinomas from a Defined Founder Population Associated with Patient Outcome

PLoS ONE

Volumn 7, Issue 9, 2012, Pages

  Wojnarowicz, Paulina M ^a   Oros, Kathleen Klein ^b   Quinn, Michael C J ^c   Arcand, Suzanna L ^d   Gambaro, Karen ^a   Madore, Jason ^c   Birch, Ashley H ^a   de Ladurantaye, Manon ^c   Rahimi, Kurosh ^c   Provencher, Diane M ^c,e   Mes Masson, Anne Marie ^c,e   Greenwood, Celia M T ^a,b   Tonin, Patricia N ^a,d  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^d RESEARCH INSTITUTE OF THE MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^e UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; K RAS PROTEIN; PROTEIN P53;

ARTICLE; CANCER GRADING; CANCER SURVIVAL; CHROMOSOMAL LOCALIZATION; CHROMOSOME 13Q; CHROMOSOME 16Q; CHROMOSOME 17P; CHROMOSOME 17Q; CHROMOSOME 20Q; CHROMOSOME 22Q; CHROMOSOME 3Q; CHROMOSOME 4Q; CHROMOSOME 5Q; CHROMOSOME 6Q; CHROMOSOME 8Q; CHROMOSOME ABERRATION; CHROMOSOME GAIN; CHROMOSOME LOSS; CHROMOSOME XP; CONTROLLED STUDY; CORRELATIONAL STUDY; DISEASE FREE SURVIVAL; ETHNIC GROUP; FEMALE; FRAMESHIFT MUTATION; FRENCH CANADIAN; GENE DELETION; GENE EXPRESSION; GENE FREQUENCY; GENE IDENTIFICATION; GENE INSERTION; GENE LOCATION; GENETIC ASSOCIATION; GENOME ANALYSIS; GENOMICS; GENOTYPE; HIGH GRADE OVARIAN SEROUS CARCINOMA; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MISSENSE MUTATION; MUTATIONAL ANALYSIS; NONSENSE MUTATION; NUCLEOTIDE SEQUENCE; NULL ALLELE; OVARY CARCINOMA; OVERALL SURVIVAL; P53 GENE; POPULATION GENETICS; PROTEIN EXPRESSION; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR SUPPRESSOR GENE;

CANADA; CHROMOSOME ABERRATIONS; COMPARATIVE GENOMIC HYBRIDIZATION; CYSTADENOCARCINOMA, SEROUS; FEMALE; FOUNDER EFFECT; GENES, RAS; HUMANS; MUTATION; NEOPLASM GRADING; OVARIAN NEOPLASMS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTO-ONCOGENE PROTEINS B-RAF; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84866682056     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0045484     Document Type: Article

References (62)

1. Agarwal R, Kaye SB, (2003) Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nature reviews Cancer 3: 502-516.
2. Seidman JD, Horkayne-Szakaly I, Haiba M, Boice CR, Kurman RJ, et al. (2004) The histologic type and stage distribution of ovarian carcinomas of surface epithelial origin. International journal of gynecological pathology: official journal of the International Society of Gynecological Pathologists 23: 41-44.
3. Rosen DG, Yang G, Liu G, Mercado-Uribe I, Chang B, et al. (2009) Ovarian cancer: pathology, biology, and disease models. Frontiers in bioscience: a journal and virtual library 14: 2089-2102.
4. Lynch HT, Casey MJ, Snyder CL, Bewtra C, Lynch JF, et al. (2009) Hereditary ovarian carcinoma: heterogeneity, molecular genetics, pathology, and management. Molecular oncology 3: 97-137.
5. Ahmed AA, Etemadmoghadam D, Temple J, Lynch AG, Riad M, et al. (2010) Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. The Journal of pathology 221: 49-56.
6. Kobel M, Reuss A, Bois A, Kommoss S, Kommoss F, et al. (2010) The biological and clinical value of p53 expression in pelvic high-grade serous carcinomas. The Journal of pathology 222: 191-198.
7. Bernardini MQ, Baba T, Lee PS, Barnett JC, Sfakianos GP, et al. (2010) Expression signatures of TP53 mutations in serous ovarian cancers. BMC cancer 10: 237.
8. TCGA (2011) Integrated genomic analyses of ovarian carcinoma. Nature 474: 609-615.
9. Gorringe KL, George J, Anglesio MS, Ramakrishna M, Etemadmoghadam D, et al. (2010) Copy number analysis identifies novel interactions between genomic loci in ovarian cancer. PloS one 5.
10. Kiechle-Schwarz M, Bauknecht T, Schmidt J, Walz L, Pfleiderer A, (1995) Recurrent cytogenetic aberrations in human ovarian carcinomas. Cancer Detection and Prevention 19: 234-243.
11. Dimova I, Orsetti B, Negre V, Rouge C, Ursule L, et al. (2009) Genomic markers for ovarian cancer at chromosomes 1, 8 and 17 revealed by array CGH analysis. Tumori 95: 357-366.
12. Plisiecka-Halasa J, Dansonka-Mieszkowska A, Kraszewska E, Danska-Bidzinska A, Kupryjanczyk J, (2008) Loss of heterozygosity, microsatellite instability and TP53 gene status in ovarian carcinomas. Anticancer Research 28: 989-996.
13. Foulkes WD, Black DM, Stamp GW, Solomon E, Trowsdale J, (1993) Very frequent loss of heterozygosity throughout chromosome 17 in sporadic ovarian carcinoma. Int J Cancer 54: 220-225.
14. Dion F, Mes-Masson AM, Seymour RJ, Provencher D, Tonin PN, (2000) Allelotyping defines minimal imbalance at chromosomal region 17q25 in non-serous epithelial ovarian cancers. Oncogene 19: 1466-1472.
15. Jacobs IJ, Smith SA, Wiseman RW, Futreal PA, Harrington T, et al. (1993) A deletion unit on chromosome 17q in epithelial ovarian tumors distal to the familial breast/ovarian cancer locus. Cancer Res 53: 1218-1221.
16. Pieretti M, Cavalieri C, Conway PS, Gallion HH, Powell DE, et al. (1995) Genetic alterations distinguish different types of ovarian tumors. Int J Cancer 64: 434-440.
17. Eccles DM, Brett L, Lessells A, Gruber L, Lane D, et al. (1992) Overexpression of the p53 protein and allele loss at 17p13 in ovarian carcinoma. British journal of cancer 65: 40-44.
18. McManus DT, Murphy M, Arthur K, Hamilton PW, Russell SE, et al. (1996) p53 mutation, allele loss on chromosome 17p, and DNA content in ovarian carcinoma. The Journal of pathology 179: 177-182.
19. Godwin AK, Vanderveer L, Schultz DC, Lynch HT, Altomare DA, et al. (1994) A common region of deletion on chromosome 17q in both sporadic and familial epithelial ovarian tumors distal to BRCA1. Am J Hum Genet 55: 666-677.
20. Tavassoli M, Ruhrberg C, Beaumont V, Reynolds K, Kirkham N, et al. (1993) Whole chromosome 17 loss in ovarian cancer. Genes, chromosomes & cancer 8: 195-198.
21. Presneau N, Dewar K, Forgetta V, Provencher D, Mes-Masson AM, et al. (2005) Loss of heterozygosity and transcriptome analyses of a 1.2 Mb candidate ovarian cancer tumor suppressor locus region at 17q25.1-q25.2. Mol Carcinog 43: 141-154.
22. Wojnarowicz PM, Provencher DM, Mes-Masson AM, Tonin PN (2012) Chromosome 17q25 genes, RHBDF2 and CYGB, in ovarian cancer. International journal of oncology.
23. Sangha N, Wu R, Kuick R, Powers S, Mu D, et al. (2008) Neurofibromin 1 (NF1) defects are common in human ovarian serous carcinomas and co-occur with TP53 mutations. Neoplasia 10: 1362-1372, following 1372.
24. Pergolizzi R, Appierto V, Crosti M, Cavadini E, Cleris L, et al. (1999) Role of retinoic acid receptor overexpression in sensitivity to fenretinide and tumorigenicity of human ovarian carcinoma cells. International journal of cancer Journal international du cancer 81: 829-834.
25. Feng Q, Deftereos G, Hawes SE, Stern JE, Willner JB, et al. (2008) DNA hypermethylation, Her-2/neu overexpression and p53 mutations in ovarian carcinoma. Gynecologic oncology 111: 320-329.
26. Rathi A, Virmani AK, Schorge JO, Elias KJ, Maruyama R, et al. (2002) Methylation profiles of sporadic ovarian tumors and nonmalignant ovaries from high-risk women. Clinical cancer research: an official journal of the American Association for Cancer Research 8: 3324-3331.
27. Bruening W, Prowse AH, Schultz DC, Holgado-Madruga M, Wong A, et al. (1999) Expression of OVCA1, a candidate tumor suppressor, is reduced in tumors and inhibits growth of ovarian cancer cells. Cancer research 59: 4973-4983.
28. Birch AH, Arcand SL, Oros KK, Rahimi K, Watters AK, et al. (2011) Chromosome 3 anomalies investigated by genome wide SNP analysis of benign, low malignant potential and low grade ovarian serous tumours. PloS one 6: e28250.
29. Scriver CR, (2001) Human genetics: lessons from Quebec populations. Annual review of genomics and human genetics 2: 69-101.
30. Roy-Gagnon MH, Moreau C, Bherer C, St-Onge P, Sinnett D, et al. (2011) Genomic and genealogical investigation of the French Canadian founder population structure. Human genetics 129: 521-531.
31. Ku CS, Naidoo N, Teo SM, Pawitan Y, (2011) Regions of homozygosity and their impact on complex diseases and traits. Human genetics 129: 1-15.
32. Petitjean A, Mathe E, Kato S, Ishioka C, Tavtigian SV, et al. (2007) Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Human Mutation 28: 622-629.
33. Singer G, Oldt R, 3rd, Cohen Y, Wang BG, Sidransky D, et al (2003) Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. Journal of the National Cancer Institute 95: 484-486.
34. Kruse JP, Gu W, (2009) Modes of p53 regulation. Cell 137: 609-622.
35. Papp J, Csokay B, Bosze P, Zalay Z, Toth J, et al. (1996) Allele loss from large regions of chromosome 17 is common only in certain histological subtypes of ovarian carcinomas. British journal of cancer 74: 1592-1597.
36. Nanjundan M, Nakayama Y, Cheng KW, Lahad J, Liu J, et al. (2007) Amplification of MDS1/EVI1 and EVI1, located in the 3q26.2 amplicon, is associated with favorable patient prognosis in ovarian cancer. Cancer research 67: 3074-3084.
37. Oricchio E, Nanjangud G, Wolfe AL, Schatz JH, Mavrakis KJ, et al. (2011) The Eph-receptor A7 is a soluble tumor suppressor for follicular lymphoma. Cell 147: 554-564.
38. Calvo E, Baselga J, (2006) Ethnic differences in response to epidermal growth factor receptor tyrosine kinase inhibitors. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 24: 2158-2163.
39. Leidner RS, Fu P, Clifford B, Hamdan A, Jin C, et al. (2009) Genetic abnormalities of the EGFR pathway in African American Patients with non-small-cell lung cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 27: 5620-5626.
40. Al-Kuraya K, Siraj AK, Bavi P, Al-Jommah N, Ezzat A, et al. (2006) High epidermal growth factor receptor amplification rate but low mutation frequency in Middle East lung cancer population. Human Pathology 37: 453-457.
41. Teng YH, Tan WJ, Thike AA, Cheok PY, Tse GM, et al. (2011) Mutations in the epidermal growth factor receptor (EGFR) gene in triple negative breast cancer: possible implications for targeted therapy. Breast cancer research: BCR 13: R35.
42. Jacot W, Lopez-Crapez E, Thezenas S, Senal R, Fina F, et al. (2011) Lack of EGFR-activating mutations in European patients with triple-negative breast cancer could emphasise geographic and ethnic variations in breast cancer mutation profiles. Breast cancer research: BCR 13: R133.
43. Lamy PJ, Jacot W, (2012) Worldwide variations in EGFR somatic mutations: a challenge for personalized medicine. Diagnostic pathology 7: 13.
44. Broet P, Dalmasso C, Tan EH, Alifano M, Zhang S, et al. (2011) Genomic profiles specific to patient ethnicity in lung adenocarcinoma. Clinical cancer research: an official journal of the American Association for Cancer Research 17: 3542-3550.
45. Bilyk OO, Pande NT, Buchynska LG, (2011) Analysis of p53, p16(INK4a), pRb and Cyclin D1 expression and human papillomavirus in primary ovarian serous carcinomas. Experimental oncology 33: 150-156.
46. Dogan E, Saygili U, Tuna B, Gol M, Gurel D, et al. (2005) p53 and mdm2 as prognostic indicators in patients with epithelial ovarian cancer: a multivariate analysis. Gynecologic oncology 97: 46-52.
47. Laframboise S, Chapman W, McLaughlin J, Andrulis IL, (2000) p53 mutations in epithelial ovarian cancers: possible role in predicting chemoresistance. Cancer journal 6: 302-308.
48. Reles A, Schmider A, Press MF, Schonborn I, Friedmann W, et al. (1996) Immunostaining of p53 protein in ovarian carcinoma: correlation with histopathological data and clinical outcome. Journal of Cancer Research and Clinical Oncology 122: 489-494.
49. Yemelyanova A, Vang R, Kshirsagar M, Lu D, Marks MA, et al. (2011) Immunohistochemical staining patterns of p53 can serve as a surrogate marker for TP53 mutations in ovarian carcinoma: an immunohistochemical and nucleotide sequencing analysis. Modern pathology: an official journal of the United States and Canadian Academy of Pathology, Inc 24: 1248-1253.
50. Soussi T, Asselain B, Hamroun D, Kato S, Ishioka C, et al. (2006) Meta-analysis of the p53 mutation database for mutant p53 biological activity reveals a methodologic bias in mutation detection. Clinical cancer research: an official journal of the American Association for Cancer Research 12: 62-69.
51. Sood AK, Sorosky JI, Dolan M, Anderson B, Buller RE, (1999) Distant metastases in ovarian cancer: association with p53 mutations. Clinical cancer research: an official journal of the American Association for Cancer Research 5: 2485-2490.
52. Belt EJ, Fijneman RJ, van den Berg EG, Bril H, Delis-van Diemen PM, et al. (2011) Loss of lamin A/C expression in stage II and III colon cancer is associated with disease recurrence. European Journal of Cancer 47: 1837-1845.
53. Bos JL, (1989) ras oncogenes in human cancer: a review. Cancer research 49: 4682-4689.
54. Brosh R, Rotter V, (2009) When mutants gain new powers: news from the mutant p53 field. Nature reviews Cancer 9: 701-713.
55. Ryan KM, Vousden KH, (1998) Characterization of structural p53 mutants which show selective defects in apoptosis but not cell cycle arrest. Molecular and Cellular Biology 18: 3692-3698.
56. Tothill RW, Tinker AV, George J, Brown R, Fox SB, et al. (2008) Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clinical cancer research: an official journal of the American Association for Cancer Research 14: 5198-5208.
57. Lounis H, Provencher D, Godbout C, Fink D, Milot MJ, et al. (1994) Primary cultures of normal and tumoral human ovarian epithelium: a powerful tool for basic molecular studies. Exp Cell Res 215: 303-309.
58. Presneau N, Mes-Masson AM, Ge B, Provencher D, Hudson TJ, et al. (2003) Patterns of expression of chromosome 17 genes in primary cultures of normal ovarian surface epithelia and epithelial ovarian cancer cell lines. Oncogene 22: 1568-1579.
59. Ouellet V, Zietarska M, Portelance L, Lafontaine J, Madore J, et al. (2008) Characterization of three new serous epithelial ovarian cancer cell lines. BMC cancer 8: 152.
60. Arcand SL, Maugard CM, Ghadirian P, Robidoux A, Perret C, et al. (2008) Germline TP53 mutations in BRCA1 and BRCA2 mutation-negative French Canadian breast cancer families. Breast cancer research and treatment 108: 399-408.
61. Quinn MC, Filali-Mouhim A, Provencher DM, Mes-Masson AM, Tonin PN, (2009) Reprogramming of the transcriptome in a novel chromosome 3 transfer tumor suppressor ovarian cancer cell line model affected molecular networks that are characteristic of ovarian cancer. Molecular carcinogenesis 48: 648-661.
62. Sun W, Wright FA, Tang Z, Nordgard SH, Van Loo P, et al. (2009) Integrated study of copy number states and genotype calls using high-density SNP arrays. Nucleic acids research 37: 5365-5377.